---
title: "Catalyst Pharmaceuticals, Inc. (CPRX.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/CPRX.US.md"
symbol: "CPRX.US"
name: "Catalyst Pharmaceuticals, Inc."
industry: "Biotechnology"
datetime: "2026-05-20T07:41:22.101Z"
locales:
  - [en](https://longbridge.com/en/quote/CPRX.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/CPRX.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/CPRX.US.md)
---

# Catalyst Pharmaceuticals, Inc. (CPRX.US)

## Company Overview

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizure; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [catalystpharma.com](https://catalystpharma.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:15.000Z

**Overall: B (0.26)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 26 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 11.65% |  |
| Net Profit YoY | 12.15% |  |
| P/B Ratio | 3.77 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 3819510760.32 |  |
| Revenue | 596958000.00 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 24.50% | A |
| Profit Margin | 37.08% | A |
| Gross Margin | 88.53% | A |
| Revenue YoY | 11.65% | B |
| Net Profit YoY | 12.15% | C |
| Total Assets YoY | 26.27% | A |
| Net Assets YoY | 27.50% | A |
| Cash Flow Margin | 94.08% | C |
| OCF YoY | 11.65% | B |
| Turnover | 0.58 | B |
| Gearing Ratio | 11.76% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Catalyst Pharmaceuticals, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "11.65%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "12.15%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "3.77",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "3819510760.32",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "596958000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "24.50%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "37.08%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "88.53%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "11.65%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "12.15%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "26.27%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "27.50%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "94.08%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "11.65%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.58",
          "rating": "B"
        },
        {
          "name": "Gearing Ratio",
          "value": "11.76%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 17.26 | 32/386 | 14.24 | 13.28 | 12.22 |
| PB | 3.77 | 289/386 | 3.35 | 3.16 | 2.95 |
| PS (TTM) | 6.40 | 132/386 | 5.25 | 4.93 | 4.57 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-11T04:00:00.000Z

Total Analysts: **6**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 2 | 33% |
| Hold | 4 | 67% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 31.21 |
| Highest Target | 36.00 |
| Lowest Target | 32.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/CPRX.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/CPRX.US/norm.md)
- [Related News](https://longbridge.com/en/quote/CPRX.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/CPRX.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**